Asterand gets $6M+ Allergan milestone
Asterand, a global provider of human tissue and services to pharmaceutical companies engaged in drug discovery research, has entered into an exclusive licence agreement with multi-speciality health care company Allergan, whereby the latter obtains the rights to further develop and commercialize a series of compounds discovered and developed by Asterand to treat conditions and diseases of the eye, such as glaucoma.
The products arise from Asterand's R99 development program. They are selective, small-molecule prostaglandin receptor agonists that have been shown in preclinical studies to be effective in reducing intra-ocular pressure. Allergan plans to further develop a focused list of lead compounds and progress these through clinical development.
Allergan will pay Asterand an upfront technology access fee of $6.25 million. In addition, the firm can receive success-based development and sales milestone payments that could total up to $56.0 million, plus royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze